Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 21 2024
0mins
- Larimar Therapeutics News: Larimar Therapeutics, Inc. saw a 17.6% rise in pre-market trading after the FDA lifted a partial clinical hold on its nomlabofusp clinical program.
- Stock Market Movements: Several other stocks also experienced significant changes in pre-market trading:
- Edible Garden AG Incorporated EDBL surged by 94.5%.
- MGO Global, Inc. MGOL gained 83.6%.
- AgriFORCE Growing Systems Ltd. AGRI rose by 74.2%.
- Meta Materials Inc. MMAT increased by 59.1%.
- Other Stock Changes: Additional stock movements included Biodexa Pharmaceuticals Plc BDRX rising by 46%, Tevogen Bio Holdings Inc. TVGN gaining 24.5%, and MMTec, Inc. MTC increasing by 22.8%.
- Declines in Stock Prices: Some companies experienced declines in pre-market trading, such as Greenwave Technology Solutions, Inc. GWAV dropping by 59.2%, LuxUrban Hotels Inc. LUXH declining by 24.1%, and Scorpius Holdings, Inc. SCPX falling by 21.8%.
- Specific Company Updates: Palo Alto Networks, Inc. PANW fell by 7.9% despite posting better-than-expected earnings for its third quarter and providing guidance for the fourth quarter.
Analyst Views on BDRX
About BDRX
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
